Clinical Trials Logo

Other clinical trials

View clinical trials related to Other.

Filter by:

NCT ID: NCT03880396 Completed - Clinical trials for Squamous Cell Carcinoma of the Head and Neck

Definitive Concurrent Hypofractionated Rth With Weekly Cisplatin in Locally Advanced SCCHN

Start date: March 10, 2019
Phase:
Study type: Observational

The primary endpoint will be acute toxicity. Secondary endpoints included: late toxicity and quality of life; loco-regional control, disease free survival and overall survival.

NCT ID: NCT03880201 Completed - Clinical trials for Perfusion Index as an Early Predictor of Ulnar Nerve Sparing in Supraclavicular Block

Perfusion Index in Detection of Ulnar Nerve Sparing During Supraclavicular Block

Start date: March 20, 2019
Phase:
Study type: Observational [Patient Registry]

The aim of this study to evaluate the ability of perfusion index to detect ulnar sparing and to estimate the proper time for the perfusion index ratio to determine successful block.

NCT ID: NCT03880032 Completed - Anxiety Clinical Trials

Happy Mother-Healthy Baby: An Anxiety-focused Early Prenatal Intervention

HMHB
Start date: April 16, 2019
Phase: N/A
Study type: Interventional

In the proposed study the investigators will develop an early prenatal preventive intervention targeting anxiety and conduct a randomized controlled trial in Pakistan to test its efficacy in reducing generalized anxiety disorder and major depression in mothers in late pregnancy and the postnatal period. Investigators will evaluate the impact of the intervention on fetal and infant growth restriction as well as examine how the impact of the intervention is mediated (to elucidate mechanisms) and/or modified (to help optimize future adaptations of the program) by various social factors. A cost-effectiveness evaluation will shed light on the costs and benefits of intervention components in relation to outcomes, enabling policy-makers and public health planners to scale up this intervention according to resource budgeting requirements.

NCT ID: NCT03879785 Completed - Clinical trials for Tobacco, Alcohol, Prescription Drug, and Illicit Substance Use

TAPS-ESP: Tobacco, Alcohol, Prescription Drug, and Illicit Substance Use Electronic Spanish Platform

TASP-ESP
Start date: March 14, 2019
Phase: N/A
Study type: Interventional

This Phase 1 STTR project will develop a technology platform for delivering the TAPS Tool to a Spanish-speaking, health disparity population in a community health center. This will involve the adaptation of the TAPS into Spanish, its deployment on a self-administered mobile/tablet technology platform, and an empirical study of its preliminary validity, feasibility, and acceptability in a Spanish-speaking primary care sample. The investigators refer to this novel adaptation of the TAPS Tool as the TAPS-Electronic Spanish Platform, or TAPS-ESP.

NCT ID: NCT03879551 Completed - Clinical trials for Parkinson's Disease With Cognitive Impairment

The Effect of Repetitive Transcranial Magnetic Stimulation on Cognitive Impairment in Parkinson's Disease (PD)

Start date: March 15, 2019
Phase: N/A
Study type: Interventional

This study aims to assess the therapeutic role of rTMS on parkinson's patients with cognitive impairment. Patients diagnosed with Parkinson's Disease and cognitive impairment will be recruited. All patients will be admitted and will be allocated randomly into two groups one of which will receive real sessions of high frequency rTMS for each hemisphere for 10 consecutive sessions totally over period of 10 days with repeated booster sessions every month during the period of follow up. The other will receive sham sessions.

NCT ID: NCT03879356 Completed - Clinical trials for Using New Protocol to Prove the Role of N-acetyl Cysteine and Adequate Supportive Measures in Aluminum Phosphide Poisoning

Supportive Measures in Treatment of Aluminum Phosphide Poisoning

Start date: January 1, 2016
Phase: Phase 4
Study type: Interventional

Aluminum phosphide poisoning (ALP) is a global public health problem, and self-poisoning accounts for one-third of the world's suicide rate. In fact, in some parts of developing countries, pesticide poisoning causes more deaths than infection. ALP is very common in our government and the prognosis of the cases is usually so bad. Toxicity by ALP is caused by the liberation of phosphine gas, which causes cell hypoxia due to inhibition of oxidative phosphorylation leading to circulatory failure.

NCT ID: NCT03879304 Completed - Clinical trials for Muscular Dystrophy, Duchenne and Becker Types

Effectiveness of a Multimodal Physiotherapy Program With Virtual Reality Glasses in Duchenne and Becker.

RVDuchenne
Start date: March 15, 2021
Phase: N/A
Study type: Interventional

Duchenne's Muscular Dystrophy and Becker Dystrophy, hereafter DMD and BMD, is a serious and progressive disease that affects 1 in 3,500-6,000 males born alive. Scale 6-minute walking test, is used for determine the inclusion of children with DMD in pharmacological studies. Furthemore, is used to verify a training effectiveness assessing muscular endurance and cardio-respiratory functions. This Research evaluates the feasibility and effectiveness of a multimodal physiotherapist program with virtual reality glasses.

NCT ID: NCT03878979 Completed - Clinical trials for Head and Neck Cancer

Preoperative Immune Checkpoint Inhibitor for Patients With Primary Untreated or Recurrent/Metastatic SCCHN

Start date: July 8, 2019
Phase: Phase 2
Study type: Interventional

Nivolumab (also known as BMS-936558) before surgery to people with newly diagnosed or recurrent squamous cell carcinoma of head and neck (SCCHN).

NCT ID: NCT03878771 Completed - Clinical trials for Oral Ulcer Due to Pemphius Vularis

PRF in Management of Chronic Multiple Oral Ulcers

Start date: March 13, 2019
Phase: Phase 1
Study type: Interventional

PRF in orabase will be applied as a pack material on chronic oral ulcers of chronic multiple oral lesions compared to conventional topical steroid therapy with clobetasol propionate 0.05% in orabase. The outcomes measured are Pain alleviation as Primary outcome and Clinical improvement in terms of Ulcer size, Number and Mucositis score as Secondary outcomes. Time frame for outcomes assessment will be Daily for 7 Days regarding pain score and weekly for 2 weeks regarding clinical improvement.

NCT ID: NCT03878420 Completed - Clinical trials for Dry Age-related Macular Degeneration

Study of Photobiomodulation to Treat Dry Age-Related Macular Degeneration (LIGHTSITE II)

Start date: February 14, 2019
Phase: N/A
Study type: Interventional

This LIGHTSITE II study is a double-masked, sham-controlled, parallel design, prospective multi-site study for the use of PBM as a treatment for visual impairment in subjects with dry AMD.